Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) entered a $25 million Standby Equity Purchase Agreement (SEPA) with a Yorkville affiliate dated Feb 25, 2026 to provide up to 36 months of discretionary funding. The facility permits sales of ADSs at discounts of 97% (3-day VWAP) or 95% (1-day VWAP), subject to resale registration, trading-volume caps and a 4.99% Yorkville ownership limit. Trinity reported $48.6 million revenue for the 12 months ended Sept 30, 2025 and cited strengthened HIV testing sales and later-stage progress on its CGM+ needle-free glucose sensor following August 2025 trial results.

Positive

• $25M SEPA provides flexible capital over 36 months
• Reported $48.6M revenue for trailing 12 months ended Sep 30, 2025
• August 2025 trial: CGM+ sensor removed finger-stick calibration requirement

Negative

• ADS issuances may occur at 5–3% discount to VWAP (95%–97% pricing)
• Subject to resale registration effectiveness and trading-volume caps
• 4.99% beneficial ownership limit may constrain large single-transaction funding

News Market Reaction – TRIB

-0.04%

6 alerts

-0.04% News Effect

+3.3% Peak Tracked

-16.5% Trough Tracked

-$6K Valuation Impact

$14M Market Cap

0.7x Rel. Volume

On the day this news was published, TRIB declined 0.04%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -16.5% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6K from the company's valuation, bringing the market cap to $14M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

SEPA capacity: $25 million SEPA term: 36 months Trailing 12-month revenue: $48.6 million +5 more

8 metrics

SEPA capacity $25 million Standby Equity Purchase Agreement with Yorkville

SEPA term 36 months Period over which up to $25M of ADSs may be sold

Trailing 12-month revenue $48.6 million Twelve months ended September 30, 2025

Three-day VWAP discount 97% ADSs priced at 97% of lowest daily VWAP over three-day period

Single-day VWAP discount 95% ADSs priced at 95% of VWAP during single-day pricing period

Beneficial ownership cap 4.99% Maximum beneficial ownership for Yorkville and affiliates under SEPA

Trial results timing August 2025 Breakthrough results for needle-free glucose sensor released

Market value rule $15,000,000 Nasdaq minimum market value of publicly held shares requirement

Market Reality Check

Price: $0.7195 Vol: Volume 152,870 is slightl...

normal vol

$0.7195 Last Close

Volume Volume 152,870 is slightly below the 20-day average of 173,205. normal

Technical Shares at $0.75 are trading below the $0.91 200-day moving average and well under the $3.44 52-week high.

Peers on Argus

TRIB gained 6.99% while momentum names like INBS (+8.94%) and AIMD (+3.83%) also...

2 Up

TRIB gained 6.99% while momentum names like INBS (+8.94%) and AIMD (+3.83%) also moved up, but scanner data flags this as a stock-specific move rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Feb 20 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 20	Nasdaq MVPHS notice	Negative	-1.6%	Nasdaq notice for failing $15M public float market value requirement.
Feb 13	Nasdaq bid-price notice	Negative	-0.6%	Nasdaq notice for ADS bid staying below $1.00 for 30 days.
Feb 10	Uni-Gold manufacturing OK	Positive	+8.8%	Regulatory approval to begin offshored Uni-Gold HIV test manufacturing.
Feb 10	HbA1c system recognition	Positive	+8.8%	Premier Hb9210 HbA1c analyser earns IFCC Gold Classification for 2026.
Dec 23	Capital structure deals	Positive	+43.5%	Agreements with Perceptive to strengthen liquidity and extend credit runway.

Pattern Detected

Recent news reactions have mostly aligned with the tone: regulatory and product wins saw double‑digit gains, while Nasdaq non‑compliance notices saw modest declines.

Recent Company History

Over the last few months, Trinity Biotech has balanced operational progress with listing‑standard pressures. Positive milestones included upstream manufacturing approval for the Uni‑Gold™ HIV test and IFCC Gold Classification for the Premier Hb9210™ analyser, both on Feb 10, 2026, each followed by a 8.75% move. Capital structure moves with Perceptive on Dec 23, 2025 triggered a 43.5% rise. More recently, Nasdaq notices on minimum bid price and market value in February 2026 drew mild negative reactions. Today’s financing tool fits into this ongoing balance between growth funding and listing compliance.

Market Pulse Summary

This announcement adds a $25 million Standby Equity Purchase Agreement as a discretionary funding to...

Analysis

This announcement adds a $25 million Standby Equity Purchase Agreement as a discretionary funding tool, complementing earlier capital structure steps with Perceptive. It comes shortly after Nasdaq notices on the $1.00 bid price and $15,000,000 market-value requirements, so equity issuance terms at 97% or 95% of VWAP and a 4.99% ownership cap are important to track. Investors may watch future SEPA usage levels, revenue trends versus the reported $48.6 million, and progress on CGM+ and HIV testing to gauge execution versus dilution.

Key Terms

standby equity purchase agreement, american depositary shares, ads, volume-weighted average price, +4 more

8 terms

standby equity purchase agreement financial

"entered into a $25 million Standby Equity Purchase Agreement (“SEPA”) with an affiliate"

A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.

american depositary shares financial

"sell up to $25 million of newly issued American Depositary Shares (“ADSs”) to Yorkville"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ads financial

"Any ADSs issued under the SEPA will be priced at either 97% of the lowest"

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

volume-weighted average price financial

"priced at either 97% of the lowest daily volume-weighted average price (“VWAP”)"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

vwap financial

"95% of the VWAP during a single‑day pricing period, as set out in the agreement."

VWAP, or Volume-Weighted Average Price, is a way to find the average price of a stock throughout the trading day, giving more importance to times when more shares are traded. It helps traders see the typical price and decide whether a stock is expensive or cheap compared to its average, similar to finding the average speed during a trip by giving more weight to times when you traveled faster or slower.

beneficial ownership limit financial

"including caps related to recent trading volume and a 4.99% beneficial ownership limit"

A beneficial ownership limit is a cap on how much of a company's stock one person or entity can effectively control, counting both shares they hold directly and those they control indirectly. It matters to investors because the limit shapes who can gain controlling influence, can force sales or extra disclosures if crossed, and affects takeover chances and market liquidity—like a rule that prevents any single neighbor from owning most of the houses on a block.

continuous glucose monitoring medical

"next-generation continuous glucose monitoring platform and is currently in the later stages"

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

metabolomics medical

"Metabolomics biomarker-based bioinformatics diagnostic platform."

Study of the small molecules and chemical patterns produced by cells, tissues or body fluids, often described as the body’s short-term chemical “fingerprint.” It matters to investors because these fingerprints can reveal how a drug or treatment is working, identify disease markers, guide patient selection, or shorten development time—similar to using a snapshot to judge whether a machine is running efficiently and needs adjustment.

AI-generated analysis. Not financial advice.

- Agreement provides additional funding tool of up to $25 million over a period of up to 36 months

- Underpins the Company’s ambitions to expand its commercialisation activities and advance its innovation agenda

DUBLIN, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a $25 million Standby Equity Purchase Agreement (“SEPA”) with an affiliate of financing partner Yorkville Advisors Global (“Yorkville”). The agreement provides Trinity Biotech with an additional funding tool designed to augment the Company’s commercialisation initiatives and to support its high‑potential R&D programs.

John Gillard, Trinity Biotech President & Chief Executive Officer, commented:

“Our key strategic objectives at Trinity Biotech are to grow our existing business profitably and to advance our exciting innovation agenda, including our flagship development CGM+. This financing agreement provides us with significant additional capability to progress these objectives.”

In the trailing 12-month period ended September 30, 2025, Trinity Biotech reported revenues of $48.6 million. Recent commercial momentum has been driven in part by renewed strength in global HIV testing demand, reflecting both stronger Uni-Gold™ revenues and resumed TrinScreen production under the Company’s WHO-approved manufacturing model. The Company expects continued operational and financial progress into 2026 as international procurement activity for HIV testing normalises and as operational efficiencies under its Comprehensive Transformation Plan further enhance margin performance.

CGM+ is Trinity Biotech’s next-generation continuous glucose monitoring platform and is currently in the later stages of device development. In August 2025, the Company released breakthrough trial results on its redesigned proprietary needle-free glucose sensor, confirming the elimination of the requirement for finger-stick calibration and de-risking the commercialisation pathway for the device. The redesigned architecture also supports a differentiated, lower-waste and more cost-efficient platform designed to improve accessibility and long-term adoption. The Company also has a range of other innovations in development including its novel Epicapture cancer monitoring technology and the Metabolomics biomarker-based bioinformatics diagnostic platform.

SEPA Overview
Under the SEPA, Trinity Biotech has the right, but not the obligation, to sell up to $25 million of newly issued American Depositary Shares (“ADSs”) to Yorkville over a period of up to 36 months, subject to the terms and conditions of the agreement and the effectiveness of a resale registration statement. The discretionary nature of the facility enables the Company to access capital when it believes market conditions are appropriate.

Any ADSs issued under the SEPA will be priced at either 97% of the lowest daily volume-weighted average price (“VWAP”) during a three‑day pricing period immediately prior to the transaction date, or 95% of the VWAP during a single‑day pricing period, as set out in the agreement. The number of ADSs issuable under the SEPA is subject to certain limitations, including caps related to recent trading volume and a 4.99% beneficial ownership limit applicable to Yorkville and its affiliates.

Important Notice Regarding Summaries
The descriptions contained in this press release are summaries only, do not purport to be complete, and are qualified in their entirety by reference to the agreement filed as an exhibit to the Company’s Form 6-K filing as of this date.

Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.

Contact:	Trinity Biotech plc		RedChip Companies Inc.
	Paul Murphy		Dave Gentry, CEO
	(353)-1-2769800		(1)-407-644-4256
			(1)-800-RED-CHIP (733-2447)
			TRIB@redchip.com

FAQ

What is the size and term of Trinity Biotech's $25 million SEPA (TRIB) announced Feb 25, 2026?

The SEPA commits up to $25 million available over a 36-month period. According to the company, Trinity may sell ADSs to Yorkville when it elects, subject to agreement terms, resale registration, volume caps and a 4.99% ownership cap.

How will the SEPA pricing work for Trinity Biotech ADSs under the Feb 25, 2026 agreement?

ADSs will be priced at either 97% of 3-day VWAP or 95% of 1-day VWAP. According to the company, pricing is set per each transaction’s pricing period and includes limits tied to recent trading volume.

How much revenue did Trinity Biotech report for the trailing 12 months ended Sept 30, 2025 (TRIB)?

Trinity reported $48.6 million in revenue for the 12 months ended Sept 30, 2025. According to the company, recent commercial momentum was driven by stronger Uni-Gold revenues and resumed TrinScreen production.

What did Trinity Biotech announce about its CGM+ trial results in August 2025 (TRIB)?

The company reported trial results eliminating the need for finger-stick calibration for its CGM+ needle-free sensor. According to the company, this de-risks commercialization and supports a lower-waste, cost-efficient platform design.

What investor constraints are included in Trinity Biotech's SEPA with Yorkville (TRIB)?

The SEPA includes caps tied to recent trading volume and a 4.99% beneficial ownership limit for Yorkville. According to the company, these restrictions limit the number of ADSs issuable under the facility per transaction.

What operational drivers does Trinity Biotech expect for 2026 after the Feb 25, 2026 SEPA announcement (TRIB)?

Trinity expects continued operational and financial progress into 2026 as HIV procurement normalizes and transformation plan efficiencies improve margins. According to the company, the SEPA augments funding for commercialization and R&D priorities.